3mo
2mo
Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37610687/
Currently, available evidence consistently demonstrates and is in good agreement that, in general, the LDL-C-lowering effect of PCSK9 inhibitors is similar across genotypes, except for compound heterozygous and homozygous familial...
Genetic background slightly affects PCSK9 inhibitors’ LDL-C lowering in familial hypercholesterolemia, with reduced response in compound heterozygous and homozygous cases; clinical factors remain key for management.
2mo
This systematic review found that ready-to-use therapeutic foods (RUTFs) with improved omega-3 fatty acid profiles and lower n-6:n-3 ratios enhanced neurodevelopmental scores, DHA status, and survival in children with severe acute malnutrition.
2mo
I go by family history. If their LDL is greater than 180 I start with high dose statin and zetia. If we do not reach goal levels, I would add a PCSK9 drug. If patient does not want an injection, I may try Benpendoic acid. In some patients, aphorisms is needed
3mo
Cyclosporin A-loaded dissolving microneedles for dermatitis therapy: Development, characterisation and efficacy in a delayed-type hypersensitivity in vivo model - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38472726/
Several drugs can be used for treating inflammatory skin pathologies like dermatitis and psoriasis. However, for the management of chronic and long-term cases, topical administration is preferred over oral delivery...
A novel cyclosporin A–loaded lipid vesicle microneedle system enhanced skin delivery, reduced inflammation, and improved histological outcomes in dermatitis models, offering a safe, targeted alternative to corticosteroid-based therapies for chronic inflammatory skin conditions.